Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

X4 Pharmaceuticals, Inc. Common Stock

XFOR

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Last trade $3.04
Day change +$0.205 (+7.24%)
Day range $2.82 – $3.07
Volume 768,026
Market cap $289M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$288.98M
Price / earnings
—
Price / book
2.08×
Price / sales
17.04×
EV / sales
10.62×
EV / EBITDA
-2.29×

Profitability

Earnings per share
-$0.79
Return on assets
-34.73%
Return on equity
-57.98%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.55×
Current ratio
13.22×
Quick ratio
12.86×
Cash ratio
12.4×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$76.1M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for XFOR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$2.88M$8.81M$2.71M$2.57M$1.77M$1.97M$28.81M$1.43M
Cost of revenue$513K$1.62M$598K$364K$351K$326K$4.72M$302K
Gross profit$2.37M$7.19M$2.11M$2.2M$1.41M$1.65M$24.09M$1.13M
Selling, general and administrative$9.01M$8.5M$6.97M$7.38M$11.59M$9.53M$15.02M$15.15M
Research and development$13.34M$15.08M$15.45M$18.52M$17.34M$18.35M$18.51M$21.7M
Total operating expenses$22.36M$23.58M$22.42M$25.9M$28.92M$27.88M$33.53M$36.85M
Operating income-$19.99M-$16.39M-$20.31M-$23.7M-$27.51M-$26.23M-$9.44M-$35.72M
Interest expense-$2.19M-$2.16M-$2.13M-$2.19M-$2.26M-$2.23M-$2.2M-$2.3M
Income before taxes-$20.2M-$16.16M-$20.24M-$23.93M-$29.85M-$25.7M$316K-$39.56M
Income taxes$3K$2K$0$0-$30K$37K$34K$258K
Net income-$20.2M-$16.16M-$20.24M-$23.93M-$29.82M-$25.74M$282K-$39.82M
Net income attributable to common shareholders-$20.2M-$16.16M-$20.24M-$23.93M-$29.82M-$25.74M$282K-$39.82M
EBITDA-$19.66M-$15.39M-$20.08M-$23.48M-$27.29M-$25.88M-$8.97M-$35.44M
Basic earnings per share-$0.16-$0.13-$0.16-$0.21-$0.69-$3.47$0.04-$5.89
Diluted earnings per share-$0.16-$0.13-$0.16-$0.21-$0.69-$3.47$0.04-$5.90

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue Estimates

X4 Pharmaceuticals reported a quarterly loss of $0.16 per share, beating consensus estimates of $0.19 loss, with a 15.79% earnings surprise. The company posted revenues of $2.88 million, surpassing estimates by 43.95% and showing year-over-year growth. Despite underperforming the S&P 500 by 20.8% this year, the stock holds a Zacks Rank #2 (Buy) rating based on favorable estimate revisions.

GlobeNewswire Inc.

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

X4 Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of mavorixafor (XOLREMDI) for treating WHIM syndrome in the EU. The drug, already FDA-approved in the U.S., would be the first and only therapy available in Europe for this ultra-rare immunodeficiency disorder. Final approval from the European Commission is anticipated in Q2 2026. X4 has partnered with Norgine for commercialization in Europe, Australia, and New Zealand, with potential milestone payments up to €226 million and royalties up to the mid-twenties.

GlobeNewswire Inc.

Sitryx appoints Adam Mostafa as Chief Financial Officer

Sitryx Therapeutics has appointed Adam Mostafa as its new Chief Financial Officer, bringing over 25 years of biotech financial experience, including previous roles at X4 Pharmaceuticals and Abpro Holdings.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 28, 20251-for-30reverse split